GM-6 is under clinical development by Genervon Biopharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect GM-6’s likelihood of approval (LoA) and phase transition for Acute Ischemic Stroke took place on 08 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GM-6 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
GM-6 is under development for the treatment of amyotrophic lateral sclerosis, acute middle cerebral artery ischemic stroke and Parkinson's disease. The drug candidate is administered through intravenous bolus or intravenously as a solution. GM6 is a peptide-based drug and analog of motoneuronotrophic factor (MNTF). GM6 is an endogenous human embryonic stage neural regulatory and signaling peptide that targets apoptosis regulator BAX, free radicals, insulin receptors IGF1,IGF2, Akt and phosphatidylinositol (3,4,5)-trisphosphate. The drug candidate is developed based on the in-silico analysis platform. It was also under development for Huntington disease, Alzheimer's disease and multiple sclerosis.
Genervon Biopharmaceuticals overview
Genervon Biopharmaceuticals (Genervon) operates as a clinical stage biopharmaceutical company that offers research services. The company discovers and develops new classes of novel master regulators bio-drugs. Its products are used to treat various disorders and diseases in nervous system and vascular system. The company’s lead product GM602, under Phase 2 study, is a drug intended for the treatment of ischemic stroke. Its other pipeline products GM604 and GM608, currently under Phase 2 study, are endogenous human embryonic stage neural regulatory and signaling peptides which are intended for the treatment of amyotrophic lateral disease and Parkinson’s disease respectively. GM6, under Phase 2 clinical development, is a peptide that helps detection and self-correction of central nervous system and neurodegenerative-related pathophysiology. Genervon is headquartered in Pasadena, California, the US.
Quick View GM-6 LOA Data
|Highest Development Stage|